ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Up 36.0% in December

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) was the target of a large increase in short interest in December. As of December 15th, there was short interest totaling 52,121 shares, an increase of 36.0% from the November 30th total of 38,313 shares. Based on an average daily trading volume, of 48,432 shares, the days-to-cover ratio is currently 1.1 days. Currently, 2.8% of the shares of the stock are short sold. Currently, 2.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 48,432 shares, the days-to-cover ratio is currently 1.1 days.

ALPS Medical Breakthroughs ETF Stock Performance

SBIO traded down $0.53 during trading on Tuesday, hitting $50.79. 36,537 shares of the company traded hands, compared to its average volume of 21,525. The stock’s 50-day simple moving average is $47.90 and its two-hundred day simple moving average is $39.51. ALPS Medical Breakthroughs ETF has a 1 year low of $22.33 and a 1 year high of $52.90.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

Large investors have recently added to or reduced their stakes in the stock. Comerica Bank bought a new stake in shares of ALPS Medical Breakthroughs ETF in the 3rd quarter valued at approximately $27,000. Raymond James Financial Inc. purchased a new stake in ALPS Medical Breakthroughs ETF during the 2nd quarter valued at $82,000. Ally Invest Advisors Inc. bought a new stake in ALPS Medical Breakthroughs ETF in the second quarter worth $200,000. Sterling Investment Advisors Ltd. bought a new stake in ALPS Medical Breakthroughs ETF in the third quarter worth $315,000. Finally, Moran Wealth Management LLC purchased a new position in ALPS Medical Breakthroughs ETF during the second quarter worth $300,000.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.